Almirall - Public Comps and Valuation Multiples

Almirall Overview

About Almirall

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company’s operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Founded

1943

HQ

Employees

576

Website

almirall.es

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.1B

LTM EBITDA $218M

EV

$2.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Almirall Financials

Almirall has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $218M.

In the most recent fiscal year, Almirall achieved revenue of $1.1B and an EBITDA of $187M.

Almirall expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Almirall valuation multiples based on analyst estimates

Almirall P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$961M	$1.1B	XXX	XXX	XXX
Gross Profit	$731M	$733M	XXX	XXX	XXX
Gross Margin	76%	69%	XXX	XXX	XXX
EBITDA	$123M	$187M	XXX	XXX	XXX
EBITDA Margin	13%	18%	XXX	XXX	XXX
Net Profit	$4.6M	-$41.3M	XXX	XXX	XXX
Net Margin	0%	-4%	XXX	XXX	XXX
Net Debt	$125M	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Almirall Stock Performance

As of April 21, 2025, Almirall's stock price is EUR 9 (or $10).

Almirall has current market cap of EUR 2.0B (or $2.1B), and EV of EUR 2.0B (or $2.2B).

See Almirall trading valuation data

Almirall Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.2B	$2.1B	XXX	XXX	XXX	XXX	$0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Almirall Valuation Multiples

As of April 21, 2025, Almirall has market cap of $2.1B and EV of $2.2B.

Almirall's trades at 2.0x LTM EV/Revenue multiple, and 10.0x LTM EBITDA.

Analysts estimate Almirall's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Almirall and 10K+ public comps

Almirall Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$2.2B	XXX	XXX	XXX
EV/Revenue	2.1x	XXX	XXX	XXX
EV/EBITDA	11.7x	XXX	XXX	XXX
P/E	196.9x	XXX	XXX	XXX
P/E/Growth	1.0x	XXX	XXX	XXX
EV/FCF	-3056.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Almirall Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Almirall Valuation Multiples

Almirall's NTM/LTM revenue growth is 12%

Almirall's revenue per employee for the last fiscal year averaged $1.8M, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Almirall's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Almirall's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Almirall and other 10K+ public comps

Almirall Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	10%	XXX	XXX	XXX	XXX
EBITDA Margin	18%	XXX	XXX	XXX	XXX
EBITDA Growth	52%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	29%	XXX	XXX	XXX	XXX
Revenue per Employee	$1.8M	XXX	XXX	XXX	XXX
Opex per Employee	$1.3M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	10%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	3%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	8%	XXX	XXX	XXX	XXX
Opex to Revenue	73%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Streaming Platforms

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Explore Valuation Multiples by Industry